Circio Publishes ESGCT Presentation on circVec Platform for T-Cell Therapies
Bitget2026/10/28 09:03- Circio Holding published its ESGCT presentation on the circVec platform for next-generation gene and cell therapies.
- Heart optimization increased gene expression approximately 200-fold versus conventional mRNA-based AAV, with 95% on-target specificity.
- Nonviral circVec delivery sustained spleen expression for up to six months on one dose, versus two weeks for mVec.
- T-cell-targeted delivery produced spleen signals at all tested doses with more than two months of durability.
- Capital raised in 2026 totaled €80 million to fund the next phase of research and development.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
